Vanguard Portfolio Management
FATE icon

Vanguard Portfolio Management’s Fate Therapeutics FATE Stock Holding History

Vanguard Portfolio Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.3M Buy
4,545,893
+411,308
+10% +$761K ﹤0.01% 2133
2026
Q1 		$4.96M Buy
+4,134,585
New +$5.03M ﹤0.01% 2323

Other funds holding FATE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Portfolio Management's FATE Position: Q2 2026 in Review

Vanguard Portfolio Management increased its Fate Therapeutics (FATE) stake by 9.9% in Q2 2026, buying an estimated $761K and bringing the position to 4,545,893 shares worth $12.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2133.

Vanguard Portfolio Management first reported a position in FATE in Q1 2026 and has held it in 2 quarters since. 141 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Vanguard Portfolio Management held 4,545,893 shares of Fate Therapeutics worth $12.3M as of Q2 2026.
  • Vanguard Portfolio Management bought 411,308 Fate Therapeutics shares in Q2 2026, an estimated $761K.
  • Fate Therapeutics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2133 holding.
  • Vanguard Portfolio Management first reported a position in Fate Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 141 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.